Scottsdale, AZNCT06910306Now EnrollingIRB Ready

Recurrent Glioblastoma Clinical Trial in Scottsdale, AZ

Access cutting-edge recurrent glioblastoma treatment through this clinical trial at a research site in Scottsdale. Study-provided care at no cost to qualified participants.

Sponsored by Alpha Tau Medical LTD.

Quick Self-Assessment

See if you qualify for this Scottsdale location

Preparing your pre-screening questions…

Expert Care in Scottsdale

Access recurrent glioblastoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related recurrent glioblastoma treatment provided free

Apply for This Scottsdale Location

Check if you qualify for this recurrent glioblastoma clinical trial in Scottsdale, AZ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Scottsdale

    Convenient for AZ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Scottsdale site if eligible
  4. 4Begin participation

About This Recurrent Glioblastoma Study in Scottsdale

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of recurrent Glioblastoma

Sponsor: Alpha Tau Medical LTD.

Who Can Participate

Inclusion Criteria

Males and females ≥ 18 and ≤ 85 years of age
Patients must have histologically confirmed diagnosis of WHO grade IV glioblastoma (including variants such as gliosarcoma, giant cell glioblastoma).
Single, gadolinium-enhancing tumor recurrence ≤ 3cm in maximum diameter
Patient not amenable for surgical resection due to any of the following but not limited reasons: patient refusal, medically ineligible, surgically too high risk due to tumor location in a deep and/or eloquent location.
Prior history of central nervous system (CNS) radiation (standard dose) with 50.4-60 Gy delivered in 1.8 Gy-2.0 Gy fractions with concurrent temozolomide (if the patient has received a non-standard fractionation or radiation dose, such as 40 Gy in 15 fractions.
Patients must have a time interval ≥4 months between completion of prior radiation and trial registration and have tumor progression per RANO criteria
Patients must have a measurable disease per RANO criteria
Estimated life expectancy is more than 6 months
Target lesion amenable for coverage by the DaRT sources
Patient must either have had recent subtotal surgery/biopsy following tumor recurrence (at least 6 weeks from trial registration) or must have shown unequivocal radiographic evidence for tumor progression by contrast-enhanced MRI scan within 21 days prior to trial registration. If surgery was performed, must have a post-operative MRI scan within 21 days prior to trial registration.
Patients have recovered from prior therapy side effects and must be at least 4 weeks post administration of chemotherapies or investigational agents with the exception of nitrosureas (such as Carmustine, Fotemustine, Lomustine) which requires 42 days of washout.
Karnofsky performance score (KPS) of at least 60 documented within 14 days prior to trial registration
Patients must have adequate biological parameters as demonstrated by the following blood counts at initial screening obtained ≤ 14 days prior to starting treatment Absolute neutrophil count (ANC) ≥ 1.5 × 109/L Platelet count ≥ 100,000/mm3 (80 × 109/L) Hemoglobin (Hgb) ≥ 9 g/dL.
Patients must have the following blood chemistry levels at initial screening obtained ≤ 14 days prior to starting treatment AST (SGOT), ALT (SGPT) ≤ 2.5 × upper limit of normal range (ULN) Total bilirubin ≤ 1.5 × ULN
Effective contraception must be used by both male and female patients while on the study and for up to 3 months following treatment
Patient must have been informed about the nature of the study, and must have agreed to participate in the study, and signed the Informed Consent Form (ICF) prior to participation in any study-related activities

Exclusion Criteria

Medical contraindication to MRI (cardiac devices are allowed if MRI compatible)
More than 3 relapses per RANO criteria
Acquired and or genetic clinical bleeding tendency
Suspicious of infratentorial or leptomeningeal or intraventricular disease
Concomitant chemotherapy or any other systemic therapy not allowed in the protocol
Recent or current (within 6 weeks) therapy with VEF or a VEGFR inhibitor
Immunocompromised state due to either transplant or AIDS
Prior allergic reaction to the study drugs
History of hypertensive crisis or hypertensive encephalopathy
Uncontrolled hypertension (defined as either \>150 mm/Hg for systolic and \>90mm/Hg for diastolic)
History of a non-healing wound, ulcer, gastrointestinal bleed (\> grade 3), traumatic injury, or bone fracture within 90 days prior to registration Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT
High probability of protocol non-compliance (in opinion of investigator)
Pregnancy or lactation
Collagenous diseases, specifically systemic lupus erythematosus, scleroderma, or dermatomyositis

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Scottsdale?

Yes, this clinical trial (NCT06910306) has an active research site in Scottsdale, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Recurrent Glioblastoma Treatment Options in Scottsdale, AZ

If you're searching for recurrent glioblastoma treatment options in Scottsdale, AZ, this clinical trial (NCT06910306) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Scottsdale research site is actively enrolling participants for this clinical trial. You'll receive care from experienced recurrent glioblastoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all recurrent glioblastoma clinical trials near you to find additional studies recruiting in your area.

More Brain Cancer Trials in Scottsdale, AZ

See all brain cancer clinical trials recruiting in Scottsdale — not just this study.

Browse Brain Cancer Trials in Scottsdale →

Browse More Trials by Condition

Brain Cancer TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Scottsdale?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Scottsdale, AZ